Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.52 |
| ▸ | EGFR | P00533 | 7/20 | 0.43 |
| ▸ | CSF1R | P07333 | 7/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967358 | 0.94 | LCK (0.49) | LCKMAPK14FGFR4EGFRCSF1R | |
| SCHEMBL3977639 | 0.79 | FGFR4 (0.61) | LCKMAPK14FGFR4EGFRFGFR1 | |
| SCHEMBL3970897 | 0.79 | MAPK14 (0.61) | LCKMAPK14FGFR4EGFRCSF1R | |
| SCHEMBL6622549 | 0.78 | LCK (0.69) | LCKMAPK14FGFR4EGFRFGFR1 | |
| SCHEMBL6617874 | 0.77 | LCK (0.85) | LCKMAPK14FGFR4EGFRCSF1R | |
| SCHEMBL6620907 | 0.74 | LCK (0.68) | LCKMAPK14FGFR4EGFRFGFR1 | |
| SCHEMBL6620252 | 0.74 | MAPK14 (0.66) | LCKMAPK14FGFR4FGFR1TNK2 | |
| SCHEMBL6619138 | 0.72 | LCK (0.74) | LCKMAPK14FGFR4EGFRCSF1R | |
| SCHEMBL16072330 | 0.72 | FGFR4 (0.71) | LCKMAPK14FGFR4CSF1RFGFR1 | |
| SCHEMBL3968454 | 0.72 | LCK (0.61) | LCKMAPK14FGFR4EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | LCK 117/4885MAPK14 447/4885FGFR4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.